Huntington's disease (HD) is a heredodegenerative neurological disorder with chorea and other hyperkinetic movement disorders being part of the disease spectrum. These along with cognitive and neurobehavioral manifestations contribute significantly to patient's disability. Several classes of drugs have been used to treat the various symptoms of HD. These include typical and atypical neuroleptics along with dopamine depletors for treatment of chorea and antidepressants, GABA agonists, antiepileptic medications, cholinesterase inhibitors, antiglutamatergic drugs and botulinum toxin for treatment of other manifestations. Tetrabenazine (TBZ), a dopamine depleting medication was recently approved by the US FDA for treatment of chorea in HD. The ...
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea assoc...
<p><b>Objective:</b> To survey neurologists and obtain clinical perceptions of tetrabenazine for the...
© 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on beh...
Abstract Background Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly bindin...
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating c...
Marissa Dean, Victor W Sung Department of Neurology, Division of Movement Disorders, University of ...
The Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Tet...
Background: Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicula...
To enhance the knowledge on the long-term efficacy and safety of tetrabenazine (TBZ) in managing cho...
Background Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicular...
Background: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrosp...
Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce sch...
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea assoc...
OBJECTIVE: We sought to assess the short-term clinical effects of tetrabenazine (TBZ) on choreic mov...
IMPORTANCE: Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metab...
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea assoc...
<p><b>Objective:</b> To survey neurologists and obtain clinical perceptions of tetrabenazine for the...
© 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on beh...
Abstract Background Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly bindin...
This is a comprehensive review of the literature regarding the use of Deutetrabenazine in treating c...
Marissa Dean, Victor W Sung Department of Neurology, Division of Movement Disorders, University of ...
The Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Tet...
Background: Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicula...
To enhance the knowledge on the long-term efficacy and safety of tetrabenazine (TBZ) in managing cho...
Background Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicular...
Background: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrosp...
Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce sch...
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea assoc...
OBJECTIVE: We sought to assess the short-term clinical effects of tetrabenazine (TBZ) on choreic mov...
IMPORTANCE: Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metab...
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea assoc...
<p><b>Objective:</b> To survey neurologists and obtain clinical perceptions of tetrabenazine for the...
© 2017 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on beh...